Cutler Integrative Medicine
- Vitamin IV Therapy
- IV Therapy
- Arthritis Treatment
- Chelation Therapy
- Peptide Therapy
Beverly Hills, MI
Beverly Hills has celebrity-driven anti-aging and some of the country's most expensive concierge medicine, and peptide therapy has grown into a visible slice of the local wellness market. The clinics we track across the Golden Triangle, Beverly Drive, and Sunset Boulevard range from physician-led longevity practices to medspa-adjacent wellness offices offering sermorelin blends and growth hormone peptides. Most local prescribers have training or admitting privileges within the Cedars-Sinai and UCLA Health network. The scene here skews toward boutique practices running personalized peptide and HRT stacks for entertainment clients. The regulatory landscape shifted sharply in 2023 and 2024 when the FDA placed several widely prescribed peptides on its Category 2 bulk substances list, restricting which ingredients compounding pharmacies could legally source. That changed access overnight for BPC-157, CJC-1295, ipamorelin, and thymosin beta-4. Sermorelin and tesamorelin remain FDA-approved for specific indications, and reputable Beverly Hills clinics now draw a clearer line between approved peptides and off-label research compounds than they did two years ago.
Regulatory context
Most research peptides used in regenerative medicine (BPC-157, TB-500, CJC-1295, ipamorelin) are not FDA-approved drugs. Sermorelin and tesamorelin hold FDA approvals for specific indications. The FDA placed several peptides into Category 2 on its Bulk Drug Substances Nominated for Use in Compounding list during 2023 and 2024, restricting 503A pharmacy sourcing. Section 503A covers traditional compounding pharmacies; Section 503B covers FDA-registered outsourcing facilities held to cGMP.
The Michigan Board of Pharmacy under the Department of Licensing and Regulatory Affairs (LARA) inspects compounding pharmacies for USP compliance. Non-resident pharmacies shipping peptides into Michigan must hold a current non-resident license. The Board publishes disciplinary actions and coordinates with LARA inspectors.
Explore related care